Breakthrough Prize Winners: Honoring Pioneers in Gene Therapy and Physics

The 2026 Breakthrough Prize in Life Sciences has been awarded to three pioneering scientists whose work laid the foundation for modern gene therapy, marking a significant milestone in the treatment of inherited genetic disorders. Jean Bennett, Albert Maguire, and Katherine High were honored for their decades-long contributions to developing safe and effective gene-based treatments, particularly for rare forms of blindness and blood disorders.

The Breakthrough Prize, often referred to as the “Oscars of Science,” recognizes transformative advances in fundamental physics, life sciences, and mathematics. Each winner receives $3 million, making it one of the most lucrative awards in science. The 2026 life sciences prize specifically highlights research that has directly led to approved therapies, including Luxturna, the first gene therapy approved by the U.S. Food and Drug Administration for an inherited disease.

Jean Bennett, a physician-scientist at the Perelman School of Medicine at the University of Pennsylvania, and Albert Maguire, a pediatric ophthalmologist at the Children’s Hospital of Philadelphia, were recognized for their collaborative work on gene therapy for Leber congenital amaurosis (LCA), a rare retinal disorder that causes severe vision loss in infancy. Their research demonstrated that a functional copy of the RPE65 gene could be delivered to retinal cells using a viral vector, significantly improving vision in treated patients.

This work culminated in the development of voretigene neparvovec (Luxturna), approved by the FDA in 2017. Luxturna remains a landmark achievement as the first directly administered gene therapy approved in the United States for a genetic disease, paving the way for subsequent treatments in ophthalmology and beyond.

Katherine High, a hematologist and gene therapy researcher formerly at the Children’s Hospital of Philadelphia and now at Spark Therapeutics, was honored for her pioneering studies on adeno-associated virus (AAV) vectors as delivery mechanisms for gene therapy. Her research focused on hemophilia B, demonstrating that AAV could safely deliver a functional factor IX gene to liver cells, leading to sustained production of the clotting protein.

High’s clinical trials showed durable expression of factor IX following a single infusion, reducing or eliminating the need for regular recombinant factor infusions in patients with hemophilia B. These results provided critical proof of concept for systemic gene therapy and helped establish AAV as a leading platform for in vivo gene delivery.

Their combined efforts have not only produced FDA-approved treatments but also accelerated the broader field of genetic medicine. Over 30 gene therapies have now received regulatory approval worldwide, with many targeting rare genetic diseases that previously had no treatment options. The success of early pioneers like Bennett, Maguire, and High has encouraged investment and innovation across academia, biotechnology, and pharmaceutical industries.

In addition to the life sciences award, the 2026 Breakthrough Prizes recognized achievements in fundamental physics and mathematics. Physicists were honored for precision measurements of the muon’s magnetic moment, which may indicate physics beyond the Standard Model. Mathematicians were cited for advances in geometric analysis and partial differential equations. However, the life sciences award drew particular attention for its tangible impact on patient outcomes.

The award ceremony took place in April 2026 in Los Angeles, continuing the tradition of a televised gala hosted by prominent figures in science and entertainment. Past ceremonies have featured presentations by Silicon Valley leaders and Hollywood celebrities, underscoring the prize’s role in bridging scientific achievement with public awareness.

As gene therapy expands into new areas — including neurologic disorders, cardiovascular disease, and immunotherapy — the foundational work of this year’s laureates remains central to ongoing research. Their achievements exemplify how sustained basic science, translational research, and clinical collaboration can transform theoretical understanding into real-world medical breakthroughs.